Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
March 4, 2021 7:30 AM ESTInitiated Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients
On Track to Initiate Two Additional Clinical Trials Across Hematology Franchise in 2H 2021
On Track to Report Additional Dose-Escalation Data for SY-5609 in Select Solid Tumors in Q3 2021, with Expansion Phase of Trial Expected to Begin in 2H 2021
Well-funded with Cash Runway into 2023, Through Multiple Potential Value Drivers
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE,... More
